Biosimilars

The Pharmacy Times® Biosimilars Resource Center is a comprehensive resource for clinical news and expert insights on issues related to biosimilar drugs, a biological product that is highly similar to a reference biologic for which there are no clinically meaningful differences in terms of safety, purity, and efficacy.

Expert: Pharmacist Involvement in the Care Team Can Impact Biosimilar Adoption

May 04, 2022

Video

Sonia T. Oskouei, PharmD, vice president of biosimilars at Cardinal Health, discussed how pharmacists can impact biosimilar adoption.

Worldwide Generics Market Will Exceed $507 Billion in 4 Years

April 21, 2022

Article

US segment to hit $121.8 billion in 2022, notes market research firm.

Expert: Tracking Insulin Biosimilar Activity May Shed Light on How Managed Care Stakeholders Approach Biosimilar Formulary Decisions

April 20, 2022

Video

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, discusses what biosimilars in the pipeline are expected to launch this year.

Expert: With First Insulin Biosimilars Now in Retail Pharmacies, Pharmacists Are at the Forefront of Facilitating Insulin Biosimilar Transition for Patients

April 20, 2022

Video

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, on the results of Cardinal Health’s assessment of the current biosimilars market published in the 2022 Biosimilars Report.

Biosimilar Candidate to Ustekinumab Shows Positive Results Treating Plaque Psoriasis

April 20, 2022

Article

The phase 3, multicenter, randomized, double-blinded, comparative clinical study was evaluating the efficacy and safety of ABP 654 compared with ustekinumab in adult patients with moderate to severe plaque psoriasis.

Expert: Concerns Around Efficacy of Biosimilars Is Primary Reason for Health Care Professionals’ Hesitancy in Treatment Adoption

April 19, 2022

Video

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, on the results of Cardinal Health’s assessment of the current biosimilars market published in the 2022 Biosimilars Report.

Third Biosimilar to Bevacizumab Granted FDA Approval

April 19, 2022

Article

Bevacizumab-maly (Almysys; mAbxience) is the third biosimilar of bevacizumab (Avastin) approved in the United States.

Expert: Modern Automation, Interoperable Technology Systems in Health Care Make Pharmacy’s Future Brighter Than Ever

April 19, 2022

Video

David Pope, PharmD, CDE, chief innovation officer at OmniSYS, discusses some of the technology trends that occurred in the pharmacy space during the pandemic.

Oncology Biosimilars Enter an Era of Expansion

April 13, 2022

Article

Biosimilars could save consumers more than $100 billion in the coming years.

Survey: Retail Pharmacists Optimistic About Biosimilars, Still Have Questions

April 12, 2022

Article

With the FDA approval and launch of the first interchangeable biosimilar in the United States in 2021, retail pharmacists are poised to play an increasing role in the future uptake of biosimilars.